News
Bristol Myers Squibb Co. stock underperforms Thursday when compared to competitors
Shares of Bristol Myers Squibb Co. BMY slid 5.81% to $43.31 Thursday, on what proved to be an all-around dismal trading session for the stock market, with the S&P 500 Index SPX falling 0.37% to 6,339.39 and Dow Jones Industrial Average DJIA falling 0.74% to 44,130.98.
(Reuters) -Bristol Myers Squibb posted much better-than-expected second-quarter results on Thursday on strong sales of its ...
Bristol Myers Squibb trimmed its full-year adjusted earnings view as it reported lower second-quarter earnings due to a ...
3don MSN
Bristol Myers Beats Earnings Expectations. It’s Still Optimistic About New Schizophrenia Drug.
Cobenfy is one of the key products Bristol is counting on to take up the slack as patents on three of its top-selling drugs ...
By Michael Erman (Reuters) -Bristol Myers Squibb posted much better-than-expected second-quarter results on Wednesday on ...
Out of all of the special options we uncovered, 26 are puts, for a total amount of $1,771,839, and 16 are calls, for a total amount of $839,064. Taking into account the Volume and Open Interest on ...
Myers Squibb (BMY) is a contrarian value play with a 5.39% dividend yield, strong growth strategy, and long-term potential.
Bristol Myers Squibb said on Friday its blockbuster drug Reblozyl in combination with another therapy failed to meet the main goal of a late-stage trial to treat anemia caused by a rare bone marrow ...
Bristol Myers Squibb had a strong quarter, with key drugs old and new coming in either above or in line with Wall Street’s ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback